← Eichor
Study identifier: NCT06605404 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Pan-tumor MRD Study

Condition: Muscle Invasive Bladder Urothelial Carcinoma · Esophageal Cancer · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma  ·  Sponsor: Paradigm Health

PhaseN/A
Planned participants1350
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back. Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.

This description comes directly from the study's public registry record.

Talk to the study team

Anosheh Afghahi, MD  ·  888-662-6367  ·  anosheh.afghahi@flatiron.com

Always discuss trial participation with your own doctor first.

Locations (2)

Medical Oncology Associates of San DiegoSan Diego, California, United StatesRecruiting
Taylor Cancer Research CenterMaumee, Ohio, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06605404